
RECONNECT Fragile X syndrome clinical trial open throughout 2024
Children aged 3 to 22 years who are experiencing Fragile X syndrome-associated behavioural issues may be eligible to participate in a clinical trial in Australia. The RECONNECT study is seeking to evaluate the efficacy of a topical gel developed by Zynerba Pharmaceuticals in helping with the Fragile X-associated behaviours. The study remains open to participants through to the end of 2024.
News